Company Filing History:
4 out of 21 
4 out of 541 
Years Active: 2022-2024
Title: The Innovator Behind Groundbreaking Antibody Drug Conjugates: Jay Marshall Feingold
Introduction
Jay Marshall Feingold, an accomplished inventor based in Murray Hill, NJ, has made significant contributions to the field of medical science with his innovative work on antibody drug conjugates (ADCs). With a total of four patents to his name, Feingold focuses on the treatment of various pathological conditions, including cancer. His groundbreaking research has paved the way for more effective therapies and improved patient outcomes.
Latest Patents
Feingold's recent patents demonstrate his commitment to advancing cancer treatment. One of his notable inventions is the patent for "Dosage regimes for the administration of an anti-CD19 ADC." This patent discusses the treatment protocols for ADCs that target CD19, a promising area in cancer therapy. Another significant patent is for "Combination therapy with an anti-CD25 antibody-drug conjugate," which explores the use of ADCs in conjunction with secondary agents to enhance therapeutic effectiveness in cancer treatment.
Career Highlights
Throughout his career, Jay Marshall Feingold has been associated with prominent companies in the biotechnology sector, notably Adc Therapeutics SA and MedImmune Limited. His work in these organizations has allowed him to contribute to innovative research and the development of cutting-edge therapies, further solidifying his status as a leading inventor in the field.
Collaborations
Feingold has collaborated with several distinguished professionals in the industry, including David Rodney Ungar and Jens Wuerthner. These partnerships have likely fostered a dynamic exchange of ideas and techniques, leading to the advancement of their collective research and innovations.
Conclusion
Jay Marshall Feingold exemplifies the essence of innovation in the biotechnology realm. His contributions through multiple patents and a successful career underscore the importance of continuous research and collaboration in developing new therapeutic options for cancer treatment. As he continues to explore the potential of antibody drug conjugates, the medical community eagerly anticipates the impact of his future inventions on patient care and treatment methodologies.